Hikma Pharmaceuticals Regulatory News (HIK)

6 Jun 2007 07:00

Hikma Pharmaceuticals Plc06 June 2007 Annual General Meeting of Hikma Pharmaceuticals PLC LONDON, 6 June 2007 - Hikma Pharmaceuticals PLC ("Hikma") (LSE: HIK) (DIFX:HIK), the multinational pharmaceuticals manufacturer, will hold its AnnualGeneral Meeting today in London. At the meeting, Samih Darwazah, Chairman andChief Executive of Hikma Pharmaceuticals PLC, will make the following statement: "I am pleased to report that, as anticipated, the Group is performing wellyear-to-date. We will announce our interim results for the six months ended 30June 2007 on 5 September 2007 and will publish an update on trading at the endof June, prior to entering our close period on 7 July 2007." - ENDS - Enquiries: Hikma Pharmaceuticals PLCSusan Ringdal +44 20 7399 2760Investor Relations Director Brunswick GroupJon Coles / Justine McIlroy / Alex Tweed +44 20 7404 5959 About Hikma Hikma Pharmaceuticals PLC is a multinational pharmaceutical group focused ondeveloping, manufacturing and marketing a broad range of both branded andnon-branded generic and in-licensed pharmaceutical products. Hikma's operationsare conducted through three businesses: Generic, Branded and InjectablePharmaceuticals. Hikma's operations are based principally in the Middle East andNorth Africa ("MENA") region, the United States and Europe. In 2006, the Grouphad revenue of $317 million and profit attributable to shareholders of $55million. At 31 December 2006, the Group had over 2,443 employees. For news andother information, please visit www.hikma.com. This information is provided by RNS The company news service from the London Stock Exchange